Lymph-Node-Targeted, mKRAS-Specific Amphiphile Vaccine in Pancreatic and Colorectal Cancer: The Phase I AMPLIFY-201 Trial

Investigators treated 25 patients, 20 pancreatic and five colorectal, who were positive for minimal residual mKRAS disease after locoregional treatment in a Phase I study of fixed-dose Amph-Peptides-2P and ascending-dose Amph-CpG-7909.